Skip Navigation

A Phase I Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients with Advanced Hematologic Malignancies.

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT05024045

Study #:
STUDY00148042

Start Date:
Apr 12, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05024045

View Complete Trial Details & Eligibility at ClinicalTrials.gov